PHASE-II STUDY OF LIPOSOMAL MURAMYL TRIPEPTIDE IN OSTEOSARCOMA - THE CYTOKINE CASCADE AND MONOCYTE ACTIVATION FOLLOWING ADMINISTRATION

Purpose: A phase II trial that uses liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) in patients with relapsed osteosarcoma is underway. To determine if in vivo cytokine induction plays a role in the mechanism of action of L-MTP-PE, we investigated the circulating cytokine levels of 16 patients who were undergoing therapy. Patients and Methods: Patients had histologically proven osteosarcoma and pulmonary metastases that developed either during adjuvant chemotherapy or that were present at diagnosis and persisted despite chemotherapy. Patients were rendered disease-free by surgery. The major goal of the study was to improve the disease-free interval in this high-risk group. L-MTP-PE 2 mg/m2 was infused during a 1-hour period twice a week for 12 weeks, then once a week for 12 weeks. Serial blood samples were collected after L-MTP-PE administration and were assayed for cytokine levels (tumor necrosis factor-alpha [TNFα] interleukin-1 alpha [IL-1α], IL-1β, IL-6, interferon-gamma [IFN-γ], neopterin, C-reactive protein). Results: After the infusion of L-MTP-PE, there was rapid induction of circulating TNFα and IL-6. TNFα levels peaked 1 to 2 hours after infusion in 10 of 16 patients, whereas peak IL-6 levels were detected at 2 to 3 hours in all patients. Induction of circulating TNFα and IL-6 was evident only after the first dose of L-MTP-PE. Neither IL-1α nor IL-1β was detected in the plasma. Neopterin levels increased at 24 hours postinfusion, which indicated macrophage activation, and were not related to the induction of circulating IFN-γ. C-reactive protein was elevated in all patients at 24 hours and decreased by 72 hours. Unlike circulating TNFα and IL-6, elevations in C-reactive protein and neopterin could be detected throughout the treatment course. Conclusion: It is concluded that L-MTP-PE has specific biologic effects in patients with osteosarcoma that may be important to the drug's immunostimulatory capacity and its effectiveness as an antitumor agent. © 1992 by American Society of Clinical Oncology.